


What is claimed is:

1. A compound of formula I



(I)

wherein

- 5 X is CO or SO₂;
- R₁ and R₂ are each independently H, C₁-C₁₀alkyl optionally substituted with one or more halogen, hydroxy, C₁-C₄alkoxy, CO₂R₈, CONR₉R₁₀, C₃-C₇cycloalkyl or optionally substituted phenyl groups, or phenyl optionally substituted with one to three halogen, hydroxy, C₁-C₆haloalkyl, C₁-C₄alkoxy, CO₂R₁₁, NR₁₂R₁₃ or CN groups;
- 10 R₃ is H, F, Cl, Br or I;
- R₄ and R₅ are each independently H, NH₂, CH₂CH₂OCH₂CH₂OCH₂CH₂NH₂ or a C₁-C₆alkyl group optionally substituted with one or two CN, OR₁₄, NR₁₅R₁₆, CO₂R₁₇ or C₃-C₇cycloalkyl group,
- 15 phenyl optionally substituted with one or two halogen, CN, OR₁₄, NR₁₅R₁₆, CO₂R₁₇, COR₁₈, an optionally substituted C₁-C₆alkyl or an optionally substituted C₂-C₆alkenyl group,
- benzyl optionally substituted with one or two halogen, OR₁₄, COR₁₈, or a C₁-C₃alkyl group optionally substituted with one OR₁₄ group, or
- 20 pyridinyl optionally substituted with one or two halogen, OR₁₄, NR₁₅R₁₆ or CO₂R₁₇ groups, or
- R₄ and R₅ may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally

containing one double bond, a benzofused ring or an additional heteroatom selected from O, NR₁₉ or S;

R₆ is phenyl optionally substituted with one to three halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₀, SO₂NR₂₁R₂₂, CO₂R₂₃ or NR₂₄R₂₅ groups,

cycloheteroalkyl optionally substituted with one or more halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₀, SO₂NR₂₁R₂₂, CO₂R₂₃ or NR₂₄R₂₅ groups, or

heteroaryl optionally substituted with one or more halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₀, SO₂NR₂₁R₂₂, CO₂R₂₃ or NR₂₄R₂₅ groups;

R₈, R₁₁, R₁₇, R₁₈ and R₂₃ are each independently H or a C₁-C₆alkyl, C₃-C₇cycloalkyl, C₁-C₆haloalkyl, phenyl, C₅-C₇cycloheteroalkyl or heteroaryl group each optionally substituted;

R₉, R₁₀, R₁₂, R₁₃, R₁₅, R₁₆, R₂₁, R₂₂, R₂₄ and R₂₅ are each independently H or a C₁-C₆alkyl, C₃-C₇cycloalkyl, C₁-C₆haloalkyl, phenyl, C₅-C₇cycloheteroalkyl or heteroaryl group each optionally substituted or each of R₉ and R₁₀ or R₁₂ and R₁₃ or R₁₅ and R₁₆ or R₂₁ and R₂₂ or R₂₄ and R₂₅ may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S;

n is 0 or an integer of 1 or 2;

R₁₄ is H, C₁-C₃alkyl or C₁-C₃haloalkyl;

R₁₉ is H or C₁-C₃alkyl; and


R₂₀ is a C₁-C₆alkyl, C₃-C₇cycloalkyl, C₁-C₆haloalkyl, phenyl, C₅-C₇cycloheteroalkyl or heteroaryl group each optionally substituted; or

the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

2. The compound according to claim 1 wherein X is CO.

3. The compound according to claim 1 wherein R₁ is H.
4. The compound according to claim 1 wherein R₁ is H. The compound according to claim 1 wherein R₆ is a phenyl group optionally substituted with one or two CN, NO₂, halogen, CF₃, C₁-C₃alkoxy or CO₂R₂₃ groups.
5. The compound according to claim 2 wherein R₂ is H or C₁-C₃alkyl.
6. The compound according to claim 2 wherein R₄ and R₅ are each independently H or a C₁-C₃alkyl, phenyl or benzyl group each optionally substituted with one or two hydroxy groups or R₄ and R₅ may be taken together with the atom to which they are attached to form a pyrrolidinyl or morpholinyl ring each optionally substituted with one carboxy group.
7. The compound according to claim 5 wherein R₆ is phenyl optionally substituted in the 3-position with CF₃.
8. The compound according to claim 7 wherein R₁ is H.
9. The compound according to claim 7 wherein R₁ is H. The compound according to claim 1 selected from the group consisting of:
N-(4-hydroxyphenyl)-3-(6-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydrodipyrzolo[3,4-b:3,4-d]pyridin-2(1H)-yl)benzamide;
N-(2,2-dimethoxyethyl)-N-methyl-3-(6-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydrodipyrzolo[3,4-b:3,4-d]pyridin-2(1H)-yl)benzamide;
6-methyl-2-[3-(1-pyrrolidinylcarbonyl)phenyl]-4-[3-(trifluoromethyl)phenyl]-1,6-dihydrodipyrzolo[3,4-b:3,4-d]pyridin-3(2H)-one;
(2R)-1-[3-(6-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydrodipyrzolo[3,4-b:3,4-d]pyridin-2(1H)-yl)benzoyl]-2-pyrrolidinecarboxylic acid;
N-(3,4-dihydroxybenzyl)-3-(6-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydrodipyrzolo[3,4-b:3,4-d]pyridin-2(1H)-yl)benzamide;
N-(2-hydroxypropyl)-3-(6-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydrodipyrzolo[3,4-b:3,4-d]pyridin-2(1H)-yl)benzamide;
1-[2-chloro-5-[6-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydrodipyrzolo[3,4-b:3',4'-d]pyridin-2(1H)-yl]benzoyl]-D-proline;

- 2-(4-chloro-3-(((2R)-2-(hydroxymethyl)pyrrolidin-1-yl)carbonyl)phenyl)-6-methyl-4-[3-(trifluoromethyl)phenyl]-1,6-dihydrodipyrzolo[3,4-b:3,4-d]pyridin-3(2H)-one;
 N-(4-hydroxyphenyl)-4-{6-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydrodipyrzolo[3,4-b:3',4'-d]pyridin-2(1H)-yl}benzamide;
 5 N-(2-hydroxyphenyl)-4-{6-methyl-3-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydrodipyrzolo[3,4-b:3',4'-d]pyridin-2(1H)-yl}benzamide;
 6-methyl-2-[4-(4-morpholinylcarbonyl)phenyl]-4-[3-(trifluoromethyl)phenyl]-1,6-dihydrodipyrzolo[3,4-b:3,4-d]pyridin-3(2H)-one;
 N-[4-(2-hydroxyethyl)phenyl]-4-(6-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydrodipyrzolo[3,4-b:3,4-d]pyridin-2(1H)-yl)benzamide;
 10 N-[3-(1-hydroxyethyl)phenyl]-4-(6-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydrodipyrzolo[3,4-b:3,4-d]pyridin-2(1H)-yl)benzamide;
 N-[3-(hydroxymethyl)phenyl]-4-(6-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydrodipyrzolo[3,4-b:3,4-d]pyridin-2(1H)-yl)benzamide;
 15 N-(5-hydroxypentyl)-4-(6-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydrodipyrzolo[3,4-b:3,4-d]pyridin-2(1H)-yl)benzenesulfonamide;
 N-benzyl-4-[6-methyl-3-oxo-4-(3-trifluoromethyl-phenyl)-3,6-dihydro-1H-1,2,5,6,7-pentaaza-as-indacen-2-yl]-benzenesulfonamide;
 N-(2-hydroxyethyl)-4-(6-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydrodipyrzolo[3,4-b:3,4-d]pyridin-2(1H)-yl)benzenesulfonamide;
 20 methyl ((([4-(6-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydrodipyrzolo[3,4-b:3,4-d]pyridin-2(1H)-yl)phenyl]sulfonyl)amino)acetate);
 N-cyclopropylmethyl-4-[6-methyl-3-oxo-4-(3-trifluoromethyl-phenyl)-3,6-dihydro-1H-1,2,5,6,7-pentaaza-as-indacen-2-yl]-benzenesulfonamide;
 25 ((([4-(6-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydrodipyrzolo[3,4-b:3,4-d]pyridin-2(1H)-yl)phenyl]sulfonyl)amino)acetic acid;
 the stereoisomers thereof; and
 the pharmaceutically acceptable salts thereof.
- 30 10. A method for the treatment of an immune disorder related to or affected by the immune regulatory protein B7-1 which comprises providing a patient in need thereof an immunotherapeutically effective amount of a compound of formula I



(I)

wherein

X is CO or SO₂;

R₁ and R₂ are each independently H, C₁-C₁₀alkyl optionally substituted with one
 5 or more halogen, hydroxy, C₁-C₄alkoxy, CO₂R₈, CONR₉R₁₀, C₃-
 C₇cycloalkyl or optionally substituted phenyl groups, or
 phenyl optionally substituted with one to three halogen, hydroxy, C₁-
 C₆haloalkyl, C₁-C₄alkoxy, CO₂R₁₁, NR₁₂R₁₃ or CN groups;

R₃ is H, F, Cl, Br or I;

10 R₄ and R₅ are each independently H, NH₂, CH₂CH₂OCH₂CH₂OCH₂CH₂NH₂ or a
 C₁-C₆alkyl group optionally substituted with one or two
 CN, OR₁₄, NR₁₅R₁₆, CO₂R₁₇ or C₃-C₇cycloalkyl group,
 phenyl optionally substituted with one or two halogen, CN, OR₁₄, NR₁₅R₁₆,
 CO₂R₁₇, COR₁₈, an optionally substituted C₁-C₆alkyl or an optionally
 15 substituted C₂-C₆alkenyl group,

benzyl optionally substituted with one or two halogen, OR₁₄, COR₁₈, or a
 C₁-C₃alkyl group optionally substituted with one OR₁₄ group, or
 pyridinyl optionally substituted with one or two halogen, OR₁₄, NR₁₅R₁₆ or
 CO₂R₁₇ groups, or

20 R₄ and R₅ may be taken together with the atom to which they are attached
 to form an optionally substituted 5- to 7-membered ring optionally
 containing one double bond, a benzofused ring or an additional
 heteroatom selected from O, NR₁₉ or S;

R_6 is phenyl optionally substituted with one to three halogen, NO_2 , CN, hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkylthio, C_1 - C_6 haloalkyl, C_1 - C_6 alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR_{20} , $SO_2NR_{21}R_{22}$, CO_2R_{23} or $NR_{24}R_{25}$ groups,

5 cycloheteroalkyl optionally substituted with one or more halogen, NO_2 , CN, hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkylthio, C_1 - C_6 haloalkyl, C_1 - C_6 alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR_{20} , $SO_2NR_{21}R_{22}$, CO_2R_{23} or $NR_{24}R_{25}$ groups, or

10 heteroaryl optionally substituted with one or more halogen, NO_2 , CN, hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkylthio, C_1 - C_6 haloalkyl, C_1 - C_6 alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR_{20} , $SO_2NR_{21}R_{22}$, CO_2R_{23} or $NR_{24}R_{25}$ groups;

15 R_8 , R_{11} , R_{17} , R_{18} and R_{23} are each independently H or a C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 haloalkyl, phenyl, C_5 - C_7 cycloheteroalkyl or heteroaryl group each optionally substituted;

20 R_9 , R_{10} , R_{12} , R_{13} , R_{15} , R_{16} , R_{21} , R_{22} , R_{24} and R_{25} are each independently H or a C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 haloalkyl, phenyl, C_5 - C_7 cycloheteroalkyl or heteroaryl group each optionally substituted or each of R_9 and R_{10} or R_{12} and R_{13} or R_{15} and R_{16} or R_{21} and R_{22} or R_{24} and R_{25} may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S;

25 n is 0 or an integer of 1 or 2;

R_{14} is H, C_1 - C_3 alkyl or C_1 - C_3 haloalkyl;

R_{19} is H or C_1 - C_3 alkyl; and

R_{20} is a C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 haloalkyl, phenyl, C_5 - C_7 cycloheteroalkyl or heteroaryl group each optionally substituted; or

the stereoisomers thereof or the pharmaceutically acceptable salts thereof.


30 11. The method according to claim 10 wherein said disorder is transplant rejection.

12. The method according to claim 10 wherein said disorder is an autoimmune disease.

13. The method according to claim 10 wherein said disorder is graft vs.
5 host disease.

14. The method according to claim 12 wherein said disease is multiple sclerosis or rheumatoid arthritis.

10 15. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I



(I)

wherein

- 15 X is CO or SO₂;
 R₁ and R₂ are each independently H, C₁-C₁₀alkyl optionally substituted with one or more halogen, hydroxy, C₁-C₄alkoxy, CO₂R₈, CONR₉R₁₀, C₃-C₇cycloalkyl or optionally substituted phenyl groups, or
 phenyl optionally substituted with one to three halogen, hydroxy, C₁-
 20 C₆haloalkyl, C₁-C₄alkoxy, CO₂R₁₁, NR₁₂R₁₃ or CN groups;
 R₃ is H, F, Cl, Br or I;
 R₄ and R₅ are each independently H, NH₂, CH₂CH₂OCH₂CH₂OCH₂CH₂NH₂ or a C₁-C₆alkyl group optionally substituted with one or two
 CN, OR₁₄, NR₁₅R₁₆, CO₂R₁₇ or C₃-C₇cycloalkyl group,

phenyl optionally substituted with one or two halogen, CN, OR₁₄, NR₁₅R₁₆, CO₂R₁₇, COR₁₈, an optionally substituted C₁-C₆alkyl or an optionally substituted C₂-C₆alkenyl group,

benzyl optionally substituted with one or two halogen, OR₁₄, COR₁₈, or a

5 C₁-C₃alkyl group optionally substituted with one OR₁₄ group, or pyridinyl optionally substituted with one or two halogen, OR₁₄, NR₁₅R₁₆ or CO₂R₁₇ groups, or

R₄ and R₅ may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally

10 containing one double bond, a benzofused ring or an additional heteroatom selected from O, NR₁₉ or S;

R₆ is phenyl optionally substituted with one to three halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₀, SO₂NR₂₁R₂₂, CO₂R₂₃ or

15 NR₂₄R₂₅ groups,

cycloheteroalkyl optionally substituted with one or more halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₀, SO₂NR₂₁R₂₂, CO₂R₂₃ or NR₂₄R₂₅ groups, or

20 heteroaryl optionally substituted with one or more halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₀, SO₂NR₂₁R₂₂, CO₂R₂₃ or NR₂₄R₂₅ groups;

R₈, R₁₁, R₁₇, R₁₈ and R₂₃ are each independently H or a C₁-C₆alkyl, C₃-C₇ cycloalkyl, C₁-C₆haloalkyl, phenyl, C₅-C₇cycloheteroalkyl or heteroaryl group each optionally substituted;

25 R₉, R₁₀, R₁₂, R₁₃, R₁₅, R₁₆, R₂₁, R₂₂, R₂₄ and R₂₅ are each independently H or a C₁-C₆alkyl, C₃-C₇cycloalkyl, C₁-C₆haloalkyl, phenyl, C₅-C₇cycloheteroalkyl or heteroaryl group each optionally substituted or each of R₉ and R₁₀ or

30 R₁₂ and R₁₃ or R₁₅ and R₁₆ or R₂₁ and R₂₂ or R₂₄ and R₂₅ may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S;

n is 0 or an integer of 1 or 2;

R₁₄ is H, C₁-C₃alkyl or C₁-C₃haloalkyl;

R₁₉ is H or C₁-C₃alkyl; and

5 R₂₀ is a C₁-C₆alkyl, C₃-C₇cycloalkyl, C₁-C₆haloalkyl, phenyl, C₅-C₇cyclo-
heteroalkyl or heteroaryl group each optionally substituted; or
the stereoisomers thereof or the pharmaceutically acceptable salts thereof.


16. The composition according to claim 15 having a formula I compound
wherein X is CO.
10

17. The composition according to claim 16 having a formula I compound
wherein R₁ is H.

18. The composition according to claim 17 having a formula I compound
15 wherein R₂ is H or CH₃.

19. The composition according to claim 18 having a formula I compound
wherein R₆ is phenyl optionally substituted in the 3-position with CF₃.

20. A process for the preparation of a compound of formula Ia



(Ia)

wherein

- R₁ and R₂ are each independently H, C₁-C₁₀alkyl optionally substituted with one or more halogen, hydroxy, C₁-C₄alkoxy, CO₂R₈, CONR₉R₁₀, C₃-C₇cycloalkyl or optionally substituted phenyl groups, or
- 5 phenyl optionally substituted with one to three halogen, hydroxy, C₁-C₆haloalkyl, C₁-C₄alkoxy, CO₂R₁₁, NR₁₂R₁₃ or CN groups;
- R₃ is H, F, Cl, Br or I;
- R₄ and R₅ are each independently H, NH₂, CH₂CH₂OCH₂CH₂OCH₂CH₂NH₂ or a
- 10 C₁-C₆alkyl group optionally substituted with one or two CN, OR₁₄, NR₁₅R₁₆, CO₂R₁₇ or C₃-C₇cycloalkyl group, phenyl optionally substituted with one or two halogen, CN, OR₁₄, NR₁₅R₁₆, CO₂R₁₇, COR₁₈, an optionally substituted C₁-C₆alkyl or an optionally substituted C₂-C₆alkenyl group,
- benzyl optionally substituted with one or two halogen, OR₁₄, COR₁₈, or a
- 15 C₁-C₃alkyl group optionally substituted with one OR₁₄ group, or pyridinyl optionally substituted with one or two halogen, OR₁₄, NR₁₅R₁₆ or CO₂R₁₇ groups, or
- R₄ and R₅ may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally
- 20 containing one double bond, a benzofused ring or an additional heteroatom selected from O, NR₁₉ or S;
- R₆ is phenyl optionally substituted with one to three halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₀, SO₂NR₂₁R₂₂, CO₂R₂₃ or
- 25 NR₂₄R₂₅ groups,
- cycloheteroalkyl optionally substituted with one or more halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₀, SO₂NR₂₁,R₂₂, CO₂R₂₃ or NR₂₄R₂₅ groups, or
- 30 heteroaryl optionally substituted with one or more halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₀, SO₂NR₂₁R₂₂, CO₂R₂₃ or NR₂₄R₂₅ groups;

R_8 , R_{11} , R_{17} , R_{18} and R_{23} are each independently H or a C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 haloalkyl, phenyl, C_5 - C_7 cycloheteroalkyl or heteroaryl group each optionally substituted;

5 R_9 , R_{10} , R_{12} , R_{13} , R_{15} , R_{16} , R_{21} , R_{22} , R_{24} and R_{25} are each independently H or a C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 haloalkyl, phenyl, C_5 - C_7 cycloheteroalkyl or heteroaryl group each optionally substituted or each of R_9 and R_{10} or R_{12} and R_{13} or R_{15} and R_{16} or R_{21} and R_{22} or R_{24} and R_{25} may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from
10 O, N or S;


n is 0 or an integer of 1 or 2;

R_{14} is H, C_1 - C_3 alkyl or C_1 - C_3 haloalkyl;

R_{19} is H or C_1 - C_3 alkyl; and

15 R_{20} is a C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 haloalkyl, phenyl, C_5 - C_7 cycloheteroalkyl or heteroaryl group each optionally substituted

which process comprises reacting a compound of formula II



(II)

wherein R_1 , R_2 , R_3 and R_6 are defined hereinabove with an amine, HNR_4R_5 , in the presence of an activating agent and a solvent.

20